ABT 107)
- CAS No.
- 855291-54-2
- Chemical Name:
- ABT 107)
- Synonyms
- ABT 107);ABT-107 (ABT107;(R)-3-((6-(1H-Indol-5-yl)pyridazin-3-yl)oxy)quinuclidine;1-Azabicyclo[2.2.2]octane, 3-[[6-(1H-indol-5-yl)-3-pyridazinyl]oxy]-, (3R)-
- CBNumber:
- CB34844432
- Molecular Formula:
- C19H20N4O
- Molecular Weight:
- 320.39
- MDL Number:
- MOL File:
- 855291-54-2.mol
| Boiling point | 598.0±50.0 °C(Predicted) |
|---|---|
| Density | 1.33±0.1 g/cm3(Predicted) |
| pka | 16.01±0.30(Predicted) |
| form | Solid |
| color | White to off-white |
| FDA UNII | SXS38HR98H |
ABT 107) Chemical Properties,Uses,Production
Uses
ABT-107 is a selective α7 neuronal nicotinic receptor agonist. ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions[1][2].
in vivo
ABT-107 exhibits good bioavailability in mouse (orally, 51.1%; intraperitoneally,100%), rat (orally, 81.2%; intraperitoneally, 100.0%), and monkey (orally, 40.6%; intramuscularly,
100%), and good CNS penetration in rodents with a brain/plasma ratio of 1[1].
ABT-107 (0.01-1 μmol/kg i.p., 15 min before sacrifice) produces a dose-dependent increase in ERK1/2 and CREB[1].
ABT-107 (0.01, 0.1, and 1.0 mg/kg i.p.) increases S9-GSK3 and decreases p-tau in mouse cortex and hippocampus in mice[1].
ABT-107 (5 mg/kg/day i.p.) infusion attenuates tau hyperphosphorylation in AD transgenic APP-tau mice[1].
| Animal Model: | Rats (male Sprague-Dawley; 350-380 g b.wt.)[1]. |
| Dosage: | 1, 3 μmol/kg. |
| Administration: | I.P. daily for 3 consecutive days. |
| Result: | Induced a significant, dose-dependent increase in ACh release by day 3 of repeated administration. Higher doses may be required to evoke ACh release in naive rats not engaged in stimulated, i.e., cognitive-related behavior. |
| Animal Model: | Female TAPP (and wild-type littermates) mice[1]. |
| Dosage: | 1 mg/kg. |
| Administration: | Continuous subcutaneous infusion for 2 weeks. |
| Result: | Produced a dose-dependent increase in Ser9 phosphorylation in the cingulate cortex 15 min after acute administration in mice. |
References
[1] R Scott Bitner, et al. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease. J Pharmacol Exp Ther. 2010 Sep 1;334(3):875-86. DOI:10.1124/jpet.110.167213
[2] Tanuja Bordia, et al. The α7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions. Exp Neurol. 2015 Jan;263:277-84. DOI:10.1016/j.expneurol.2014.09.015
ABT 107) Preparation Products And Raw materials
Raw materials
Preparation Products
ABT 107) Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Hangzhou MolCore BioPharmatech Co.,Ltd. | +86-057181025280; +8617767106207 | sales@molcore.com | China | 49734 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; | support@targetmol.com | United States | 39031 | 58 |
| Aladdin Scientific | tp@aladdinsci.com | United States | 52924 | 58 | |
| BOC Sciences | 1-631-485-4226; 16314854226 | info@bocsci.com | United States | 12952 | 65 |
| Shanghai Beckham Medical Technology Co., Ltd | 021-13816613772 13816613772 | huahero21@sina.com | China | 2037 | 55 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 15801484223; | psaitong@jm-bio.com | China | 29770 | 58 |
| Kaifeng Mingren Pharmaceutical Co.,LTD | 0371-65741762 | sales@hasunny.com | China | 2380 | 58 |
| TargetMol Chemicals Inc. | 4008200310 | marketing@tsbiochem.com | China | 24989 | 58 |
| Shanghai Tachizaki Biomedical Research Center | 18014399201 | sales@chemlab-tachizaki.com | China | 2680 | 58 |
| Foshan Heshuo Pharm technology Co., ltd | 15363639686 | heshuoyiyao@hotmail.com | China | 2373 | 58 |
